Dr. Surbhi Singhal

About Dr. Singhal

Dr. Surbhi Singhal treats pleural mesothelioma, lung cancer and thymic carcinoma as a thoracic oncologist at UC Davis Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center. She completed her hematology-oncology fellowship at Stanford University School of Medicine, where she developed expertise in managing asbestos-related cancers and treatment approaches for older adults with thoracic malignancies.

Dr. Singhal contributes to research on new treatment strategies for thoracic cancers including mesothelioma and lung cancer. Her published work explores how cancer spreads to the brain, how cancer detection methods continue to improve and how older adults respond to lung cancer treatments. Board certified in hematology-oncology, she brings both clinical expertise and research experience to her practice.

Close Button

Full Name

Diagnosis Please Select Mesothelioma Asbestosis Lung Cancer No Diagnosis Other Unknown

Zip Code

Email

Phone Number

Preferred Method of Contact Please Select Call Text

Message

Full Name

Get Connected Now

By clicking Get Connected Now, you agree to be contacted by Asbestos.com’s Patient Advocates with health-related information and services via call, text/SMS using an automated dialing platform and/or email at the telephone number and/or email you provided. Std. msg./data rates apply and your consent to such contact/marketing is not required for purchase of services. You also agree to our Privacy Policy and Terms of Service, including the agreement to arbitrate disputes.

Medical Education & Expertise

• UC Davis Comprehensive Cancer Center
• Stanford University School of Medicine (Fellowship)
• Stanford University School of Medicine (Residency)
• University of Wisconsin (M.D.)
• University of Minnesota (B.S.)

​Associations, Awards & Recognition

• Academic Senate Travel Award, University of California Davis, 2025
• Arnold P. Gold Foundation Humanism and Excellence in Teaching, 2019
• Best Clinical Teaching, Stanford Internal Medicine, 2019
• Butler-Williams Scholars Program, National Institute on Aging, 2023
• Clinical Innovation Fund Award, Stanford Cancer Institute, 2022
• Conquer Cancer Merit Award, American Society of Clinical Oncology, 2023
• Health in Aging Foundation New Investigator Award, American Geriatrics Society, 2025
• Member, Alpha Omega Alpha
• Member, American Society of Clinical Oncology
• Member, International Association for the Study of Lung Cancer
• Member, International Cancer and Aging Research Group

Why Choose Dr. Singhal for Pleural Mesothelioma?

Patients benefit from Dr. Singhal’s team-based approach that coordinates care with pharmacists, nurses and local oncologists. Her research on aging and cancer helps her create treatment plans tailored to older patients’ specific needs and health goals.

Dr. Singhal provides access to clinical trials testing new therapies for asbestos-related thoracic cancers. She explains your diagnosis and treatment options clearly and treats every patient with the care she would provide her own family.

Publications of Dr. Singhal

• Singhal, S. et al. (2026, January). The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study. Retrieved from https://www.annalsofoncology.org/article/S0923-7534(25)04931-2/fulltext
• Singhal, S. et al. (2025, December). Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes. Retrieved from https://www.jtocrr.org/article/S2666-3643(25)00132-8/fulltext
• Singhal, S. et al. (2025, October). Older Adult Participation in Early-Phase Lung Cancer Clinical Trials, 1998 to 2020. Retrieved from https://www.jtocrr.org/article/S2666-3643(25)00090-6/fulltext
• Singhal, S. et al. (2025, September). Cancer in a drop: Advances in liquid biopsy in 2024. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1040842825001647?via%3Dihub
• Singhal, S. et al. (2019, July). Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care—A Systematic Review. Retrieved from https://www.jpsmjournal.com/article/S0885-3924(19)30132-0/fulltext